<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Comparison of methods for endovenous ablation for chronic venous disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Comparison of methods for endovenous ablation for chronic venous disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Comparison of methods for endovenous ablation for chronic venous disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ellen D Dillavou, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Misaki Kiguchi, MD, MBA, FACS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph L Mills, Sr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Eidt, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1053581786"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Endovenous ablation is a minimally invasive, highly effective treatment that can be performed in an office-based setting. Venous ablation is appropriate for patients with persistent symptoms or cosmetic concerns in the great, small, or accessory saphenous veins, collectively known as the axial veins, and with demonstrated venous reflux on duplex ultrasound examination. </p><p>Endovenous ablation is recommended as the primary method of treating symptomatic saphenous vein reflux primarily because it is associated with less perioperative morbidity and may be more cost-effective compared with surgical ligation and stripping, which was the primary treatment method prior to the development of endovenous closure techniques. However, long-term outcomes for open and endovenous techniques are similar. </p><p>Each method of endovenous ablation (thermal, nonthermal) has unique characteristics that must be taken into consideration to meet patient and provider needs  (<a class="graphic graphic_table graphicRef119312" href="/z/d/graphic/119312.html" rel="external">table 1</a>). Understanding the technical differences and the advantages and disadvantages of each technique helps to create an individualized treatment plan and provide comprehensive care for patients with chronic venous disease.</p><p>The essential differences between the various endovenous methods for affecting venous closure, as indicated for the treatment of chronic venous disease, are reviewed here. Specific indications and techniques for their performance are reviewed separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8181.html" rel="external">"Overview of lower extremity chronic venous disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8206.html" rel="external">"Injection sclerotherapy techniques for the treatment of telangiectasias, reticular veins, and small varicose veins"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15198.html" rel="external">"Techniques for endovenous laser ablation for the treatment of lower extremity chronic venous disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8203.html" rel="external">"Techniques for radiofrequency ablation for the treatment of lower extremity chronic venous disease"</a>.)</p><p></p><p class="headingAnchor" id="H3627326140"><span class="h1">TECHNIQUE SUMMARY</span></p><p class="headingAnchor" id="H507719174"><span class="h2">Thermal ablation</span><span class="headingEndMark"> — </span>Thermal ablation techniques include radiofrequency ablation (indirect or direct) and laser ablation, which require the use of tumescent anesthesia (subcutaneous mixture of <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a>, <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>, and <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>). These techniques have been rapidly adopted as the standard of care for treating superficial axial vein reflux. Saphenous vein closure is appropriate when patients have persistent symptoms or cosmetic concerns involving the great, small, or accessory saphenous veins  (<a class="graphic graphic_figure graphicRef55019" href="/z/d/graphic/55019.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef52340" href="/z/d/graphic/52340.html" rel="external">figure 2</a>) and documented venous reflux (reflux time of &gt;500 msec) on duplex ultrasound exam.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8203.html" rel="external">"Techniques for radiofrequency ablation for the treatment of lower extremity chronic venous disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15198.html" rel="external">"Techniques for endovenous laser ablation for the treatment of lower extremity chronic venous disease"</a>.)</p><p></p><p class="headingAnchor" id="H3763388598"><span class="h3">Radiofrequency</span><span class="headingEndMark"> — </span>Radiofrequency ablation gained early attention in the 1990s for the treatment of tumors, but its application was broadened to include other conditions, including venous disease. The radiofrequency device creates a focal closed-loop alternating electrical current that ultimately induces heat damage to the vein wall endothelium. The first indirect radiofrequency device (ie, ClosureFast) was approved for use in the United States in 1999. First-generation devices were slow to use and had high recanalization rates. However, modifications in 2007 improved their effectiveness. Three-centimeter and 7 centimeter treatment coil radiofrequency catheters are available commercially. The vein is accessed and the radiofrequency catheter (65 or 100 cm length) is introduced into the vein through a 7 French sheath. Tumescent anesthesia is instilled into the perivenous tissue through a series of punctures along the target vein to completely envelope the vessel in tumescence. The use of a micropuncture needle and a motorized pump may lessen pain during delivery of the tumescent, which causes rapid hydrodissection around the vein. A direct radiofrequency catheter (Celon) is available in Europe but has not been approved for use in the United States. </p><p class="headingAnchor" id="H3808186992"><span class="h3">Laser ablation</span><span class="headingEndMark"> — </span>Endovenous laser ablation was introduced in 1999 and approved for use in the United States in 2001 [<a href="#rid1">1</a>]. Laser parameters of pullback rate, power, linear energy density, wavelength, and fiber type have all been modified to improve outcomes. A linear energy density between 60 and 100 J/cm maximizes efficacy and durability while minimizing periprocedural pain and bruising [<a href="#rid2">2-5</a>]. </p><p>Initial lasers used lower wavelengths (810, 940, 980, and 1064 nm), based on the hemoglobin chromophore  (<a class="graphic graphic_figure graphicRef63932" href="/z/d/graphic/63932.html" rel="external">figure 3</a>) [<a href="#rid6">6</a>]. Hemoglobin absorbs energy from the emitted wavelength energy, resulting in heat and eventual thrombotic occlusion of the vessel. Direct contact to the vessel wall is unnecessary [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/2883.html" rel="external">"Basic principles of medical lasers"</a>.)</p><p>Longer wavelengths have a greater affinity for water as a chromophore and are more efficient in absorbing energy, requiring lower power settings to achieve the same effect, which decreases perioperative pain and bruising compared with shorter wavelengths. One randomized trial compared 980 and 810 nm lasers, both at the same linear energy density [<a href="#rid7">7</a>]. Patients in the 980 nm laser cohort had decreased perioperative pain and bruising, but overall effectiveness was similar between the groups. Other studies have shown similar results with the 1320 and 1470 nm lasers [<a href="#rid8">8,9</a>].</p><p>Original laser fiber tips were bare, resulting in an increased incidence of vein wall perforation due to direct contact. Jacketed fibers prevent this and scatter laser energy to increase the treatment diameter. In a retrospective review, symptoms were improved when transitioning from a bare tip to the jacketed tip, and again transitioning to the radial-emitting tip [<a href="#rid10">10</a>]. Moreover, a multivariate analysis evaluating various wavelengths and tips found that increasing wavelength and protected tips correlated directly with less perioperative pain [<a href="#rid11">11</a>]. The choice of tip was a more dominant variable, but the improvement in perioperative symptomology was additive. </p><p class="headingAnchor" id="H2893226785"><span class="h2">Nonthermal ablation</span><span class="headingEndMark"> — </span>Nonthermal techniques (<a class="drug drug_general" data-topicid="9907" href="/z/d/drug information/9907.html" rel="external">polidocanol</a> endovenous microfoam [PEM], mechanochemical ablation [MOCA], and cyanoacrylate glue) provide endovenous options for veins, including those that are not amenable to thermal ablation. Nonthermal ablation eliminates the risk of thermal nerve or skin injury, and requires no tumescent anesthesia, also eliminating the need for additional needle sticks. Procedure times may also be reduced. (See  <a class="medical medical_review" href="/z/d/html/129600.html" rel="external">"Nonthermal, nontumescent ablation techniques for the treatment of lower extremity superficial venous insufficiency"</a>.)</p><p class="headingAnchor" id="H3959661457"><span class="h3">Polidocanol endovenous microfoam</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9907" href="/z/d/drug information/9907.html" rel="external">Polidocanol</a> endovenous microfoam (PEM) has been approved to treat great saphenous vein reflux and varicose veins. PEM is especially useful for very tortuous veins since it is the only method of endovenous saphenous closure that does not require catheter placement along the length of the vein. Varicose veins can also be treated using PEM in the same session as saphenous ablation. </p><p>PEM is commercially available as a standardized (uniform microbubbles) propriety foam sclerosant (ie, Varithena; 1% <a class="drug drug_general" data-topicid="9907" href="/z/d/drug information/9907.html" rel="external">polidocanol</a> foam), which was approved for use in the United States in 2013. While a physician-compounded foam (PCF) can be created using polidocanol or <a class="drug drug_general" data-topicid="10330" href="/z/d/drug information/10330.html" rel="external">sodium tetradecyl sulfate</a> with room air or carbon dioxide (CO<sub>2</sub>), the bubbles created are larger and less stable. PCF is an off-label use of these sclerosants and is associated with a higher incidence of neurologic complications compared with PEM. </p><p>PEM is typically administered through a micropuncture sheath or intravenous catheter placed near the knee, above the proximal calf perforating veins. When PEM treatment is used for great saphenous vein ablation, caution should be used to avoid extravasation of foam into large perforating veins, which could potentially cause deep vein thrombosis (DVT). </p><p class="headingAnchor" id="H3818896953"><span class="h3">Endovenous mechanochemical ablation</span><span class="headingEndMark"> — </span>Endovenous mechanochemical ablation (MOCA; ie, ClariVein) uses mechanical injury at the saphenofemoral junction to induce closure while simultaneously injecting sclerosant distally to damage the endothelium. Either <a class="drug drug_general" data-topicid="9907" href="/z/d/drug information/9907.html" rel="external">polidocanol</a> or <a class="drug drug_general" data-topicid="10330" href="/z/d/drug information/10330.html" rel="external">sodium tetradecyl sulfate</a> can be used. MOCA was approved for use in the United States in 2008. </p><p>The procedure involves venous cannulation at the knee or ankle and passage of a catheter through the target vein. An agitating wire is introduced and activated near the saphenofemoral junction injuring the vein enhancing exposure to the chemical sclerosant while simultaneously inducing spasm that traps the sclerosant to facilitate closure. </p><p>MOCA is applicable to virtually all veins that are straight enough to allow catheter placement but is especially useful for very superficial veins and those below the knee since there is no chance of nerve injury and no residual foreign body (ie, as with glue). </p><p class="headingAnchor" id="H318005295"><span class="h3">Cyanoacrylate glue</span><span class="headingEndMark"> — </span>Cyanoacrylate glue sealing (ie, VenaSeal) was approved for use in the United States in 2015. This technique seals the vein from the saphenofemoral/popliteal junction distally by injecting microbeads of cyanoacrylate glue during segmental pullback of a catheter combined with ultrasound probe compression. This tumescent-free technique is well tolerated and has been demonstrated to be safe and effective. However, the sealant remains within the vein permanently, which constitutes a foreign body. A small proportion of patients will have an allergic reaction or intolerance of the glue. There is a high cross-reactivity with other adhesive allergies. Skin testing may be indicated for patients with a tape or adhesive allergy to ensure safe use of cyanoacrylate. </p><p class="headingAnchor" id="H1205056904"><span class="h1">OUTCOME COMPARISONS</span><span class="headingEndMark"> — </span>Prior to endovenous techniques, the standard of care for managing superficial venous reflux was high ligation and stripping. Major trials demonstrating the safety and effectiveness for each endovenous treatment method are summarized  (<a class="graphic graphic_table graphicRef119310" href="/z/d/graphic/119310.html" rel="external">table 2</a>) [<a href="#rid12">12-17</a>]. Several systematic reviews have concluded that the effectiveness of minimally invasive ablation techniques and surgical high ligation and stripping is similar for treating saphenous vein reflux, but minimally invasive techniques can achieve these outcomes with less pain, fewer resources, and more rapid return to normal activities [<a href="#rid18">18-20</a>]. </p><p>Radiofrequency ablation was the first technique to be compared with surgical stripping in randomized trials. In the EVOLVEeS trial, quality-of-life scores were significantly improved for radiofrequency compared with surgical stripping and ligation [<a href="#rid21">21,22</a>]. </p><p>The effectiveness of other endovenous techniques has often been compared with radiofrequency ablation. In the ClosureFast RFA RECOVERY postmarket study, laser ablation was associated with higher rates of postprocedural pain, ecchymosis, and minor complications [<a href="#rid23">23,24</a>]. Radiofrequency ablation patients often recovered faster and were able to return to work earlier than laser patients. In a large trial that randomly assigned 500 consecutive patients with great saphenous vein reflux to radiofrequency ablation, laser ablation, ultrasound-guided foam sclerotherapy, or surgical stripping, all treatment methods were effective, but immediate technical failure was more common after foam sclerotherapy [<a href="#rid24">24</a>]. Both radiofrequency ablation and foam sclerotherapy were associated with less postoperative pain and faster recovery compared with laser ablation and vein stripping. Radiofrequency and laser ablation are also more durable compared with sclerotherapy-based ablation at long-term follow-up, requiring fewer re-interventions [<a href="#rid25">25-28</a>]. A randomized trial compared direct (Celon) and indirect (ClosureFast) radiofrequency ablation with laser ablation (980 nm) and found that indirect and laser ablation were both superior to direct closure [<a href="#rid29">29</a>].</p><p>The VeClose trial demonstrated similar improved clinical and quality-of-life scores for glue compared with radiofrequency ablation, without any difference in the effectiveness of vein closure at three months, but with significantly less ecchymosis and lower intraprocedural pain scores [<a href="#rid12">12,30</a>]. </p><p>The first trial to compare endovenous mechanochemical ablation (MOCA) with radiofrequency ablation demonstrated significantly less postoperative pain for MOCA and also an earlier return to daily activities (1.2 versus 2.4 days) [<a href="#rid31">31</a>]. Similar results of less postoperative pain and improved quality-of-life measures were noted in other studies [<a href="#rid32">32,33</a>]. In the MARADONA trial (mechanochemical endovenous ablation versus radiofrequency ablation in the treatment of primary great saphenous vein incompetence), MOCA had high technical success rates, short recovery time, and improved quality-of-life measures [<a href="#rid32">32</a>]. At one-year follow-up, 88.2 percent of the treated veins remained closed. The trial continues to enroll patients and is designed to compare clinical success and five-year follow-up data between the two cohorts. </p><p>In the LAMA trial (endovenous laser ablation versus mechanochemical ablation), the technical success was comparable between MOCA and laser ablation (92 and 94 percent, respectively), without any difference in quality-of-life measures, including early return to daily activities [<a href="#rid30">30</a>]. The intraprocedural experience of MOCA was significantly less painful for patients compared with laser ablation, but overall postprocedural pain was not significantly different. </p><p>A global multiarmed, postmarket trial is underway (VenaSeal Spectrum) to further characterize cyanoacrylate glue closure compared with vein stripping and endothermal closure across the range of subjects with chronic venous disease.</p><p>Clinical outcomes of interest, including technical success, vein recurrence, quality of life, ulcer healing, patient experience and cost for radiofrequency ablation, laser ablation, and sclerotherapy, are discussed below. Additional technical notes regarding performance of the procedures can be found in the linked topics. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8203.html" rel="external">"Techniques for radiofrequency ablation for the treatment of lower extremity chronic venous disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8206.html" rel="external">"Injection sclerotherapy techniques for the treatment of telangiectasias, reticular veins, and small varicose veins"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15198.html" rel="external">"Techniques for endovenous laser ablation for the treatment of lower extremity chronic venous disease"</a>.)</p><p></p><p class="headingAnchor" id="H1186639513"><span class="h2">Vein closure</span><span class="headingEndMark"> — </span>All methods of endovenous ablation have high initial technical success rates  (<a class="graphic graphic_table graphicRef119311" href="/z/d/graphic/119311.html" rel="external">table 3</a>) [<a href="#rid12">12-14,17,24</a>]. </p><p class="headingAnchor" id="H1918829105"><span class="h3">Radiofrequency ablation</span><span class="headingEndMark"> — </span>Closure rates with radiofrequency ablation have steadily improved with operator experience and later-generation technologies. Two meta-analyses evaluating anatomic vein closure using continuous pullback radiofrequency catheters found immediate closure rates between 89 and 94 percent for great saphenous vein ablation [<a href="#rid34">34,35</a>]. Reopening of previously occluded veins occurred in 15 to 19 percent of veins at three years and in 26 to 30 percent of veins at three- to five-year follow-up. Alterations in closure technique, and increasing probe temperature (VNUS Closure, 90<sup>º</sup>C; ClosureFast, 120<sup>º</sup>C) and ablation time, have improved immediate closure rates with reported rates as high as 99.6 percent; however, long-term data are not available for later-generation devices [<a href="#rid13">13</a>]. </p><p>Immediate closure rates for the small saphenous vein are similar to those of the great saphenous vein [<a href="#rid36">36</a>]. Immediate occlusion of perforating veins occurs in 70 to 80 percent of treated veins [<a href="#rid37">37,38</a>]. In one prospective study, at five years' follow-up, recurrent reflux developed in 19 percent of perforators previously confirmed closed [<a href="#rid39">39</a>]. Interestingly, of the total number of perforators identified with reflux, 19 percent were newly identified [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H3713290916"><span class="h3">Laser ablation</span><span class="headingEndMark"> — </span>Following laser ablation, initial technical and short-term success for treatment of the great saphenous vein ranges from 90 to 100 percent [<a href="#rid35">35,40-44</a>]. Failure of endovenous laser ablation for the great saphenous may be higher with vein diameters &gt;11 mm [<a href="#rid45">45,46</a>], but this is not always the case [<a href="#rid47">47-50</a>]. </p><p>Laser ablation of the accessory saphenous vein and small saphenous vein have shown closure rates similar to the great saphenous vein with minimal complications [<a href="#rid51">51-56</a>]. Primary success rates are 87 to 98 percent for the anterior saphenous vein and 91 to 93 percent for the small saphenous vein [<a href="#rid47">47,53,57,58</a>]. However, in one single-center retrospective review of 732 laser ablations, the failure rate was significantly higher for the anterior saphenous vein and small saphenous vein, compared with the great saphenous vein (8.8 and 13.2 percent versus 1.6 percent, respectively) [<a href="#rid47">47</a>]. In a trial that randomly assigned 106 patients with unilateral, primary small saphenous vein reflux to laser ablation or surgery, reflux was eliminated in significantly more patients treated with laser ablation (96 versus 72 percent) [<a href="#rid59">59</a>]. The high failure rate in the surgery group was primarily due to an inability to strip the small saphenous vein because of tortuosity or vein breakage. Symptomatic improvement was similar in both groups and remained the same after two years. </p><p class="bulletIndent1">For perforating veins, the SeCure Trial reported that laser ablation with a 1470 nm 400 micron fiber successfully closed 95 percent of treated veins at 10 days [<a href="#rid60">60</a>]. This rate was higher compared with perforator closure rates for radiofrequency ablation (58 percent) [<a href="#rid61">61</a>], and chemical ablation (54 percent) [<a href="#rid62">62</a>]. </p><p></p><p class="headingAnchor" id="H1930689196"><span class="h3">Polidocanol endovenous microfoam</span><span class="headingEndMark"> — </span>Although commercially available <a class="drug drug_general" data-topicid="9907" href="/z/d/drug information/9907.html" rel="external">polidocanol</a> endovenous microfoam (PEM; Varithena) and physician-compounded foam (PCF) are both polidocanol foam sclerotherapy preparations, the more uniform microbubbles make PEM more effective and less likely to cause complications compared with PCF [<a href="#rid16">16,63</a>]. PEM has reported closure rates of 85 percent when treating the great saphenous vein [<a href="#rid16">16</a>], which was similar to closure rates with PCF in one prospective randomized trial [<a href="#rid24">24</a>]. However, saphenous closure rates with foam sclerotherapy appear overall lower compared with thermal methods (77.4 versus 93.4 percent, in one laser study [<a href="#rid64">64</a>]) [<a href="#rid64">64-68</a>]. Sclerotherapy is less effective for larger veins [<a href="#rid69">69-72</a>]. Other studies have reported higher long-term success with one or more treatment sessions [<a href="#rid73">73-75</a>]. In one of these studies, 90 percent of great saphenous veins were free of recanalization with two sclerotherapy sessions over a mean 39 months of follow-up [<a href="#rid73">73</a>]. For the small saphenous vein, closure rates of 91 to 94 percent at 12 months follow-up have been reported [<a href="#rid76">76,77</a>]. Foam sclerotherapy is also an effective and durable method of eliminating reflux in perforator veins. In one observational study, 98 percent of incompetent perforators were successfully obliterated at the time of treatment; 75 percent of limbs showed persistent occlusion of perforators up to five years following treatment [<a href="#rid78">78</a>].</p><p class="headingAnchor" id="H809216747"><span class="h2">Vein recurrence</span><span class="headingEndMark"> — </span>Up to one third of patients treated with saphenous stripping have residual or recurrent varicose veins [<a href="#rid36">36,79</a>]. Following thermal ablation, randomized trials have reported a varying incidence of recurrent varicose veins ranging from 10 to 40 percent  (<a class="graphic graphic_table graphicRef119311" href="/z/d/graphic/119311.html" rel="external">table 3</a>) [<a href="#rid43">43,80-84</a>]. In large retrospective reviews of laser ablation, long-term (two to seven years) varicose vein recurrence occurred in 7 to 14 percent of patients [<a href="#rid1">1,53</a>]. Although there is some evidence that laser ablation has higher recanalization rates compared with radiofrequency ablation, this has not been borne out in high-quality studies [<a href="#rid79">79</a>]. In a comparative review, clinical recurrence rates were the same for high ligation combined with stripping of the great saphenous vein, high ligation of the saphenofemoral junction combined with laser ablation of the great saphenous vein, and laser ablation of the great saphenous vein alone over the six-year follow-up period [<a href="#rid81">81</a>]. </p><p>For foam sclerotherapy, a systematic review identified a median recurrence rate of 8.1 percent among 69 studies [<a href="#rid85">85</a>]. Foam sclerotherapy is associated with lower rates of recanalization compared with liquid sclerotherapy [<a href="#rid69">69-72</a>]. For either liquid or foam sclerotherapy, recurrence of clinical symptoms may be lower than vein recurrence [<a href="#rid86">86-88</a>]. </p><p class="headingAnchor" id="H912430546"><span class="h2">Quality of life</span><span class="headingEndMark"> — </span>Improvement in symptoms and appearance of varicose veins is reflected by venous clinical severity scales (eg, Venous Clinical Severity Score, Aberdeen Varicose Vein Symptom Score) and quality of life scores (eg, Medical Outcomes Study Short Form-36). These have been used to compare outcomes of endovenous ablation techniques [<a href="#rid23">23,27,40,41,89,90</a>]. (See  <a class="medical medical_review" href="/z/d/html/8177.html" rel="external">"Classification of lower extremity chronic venous disorders", section on 'Measures of clinical severity'</a>.)</p><p>Small trials have compared quality of life after radiofrequency or laser ablation. Patients with saphenous vein reflux were randomly assigned to radiofrequency ablation (using ClosureFAST; 67 patients) or laser ablation (using 980 nm wavelength laser; 64 patients) [<a href="#rid91">91</a>]. There were no significant differences in quality of life outcomes measures at six weeks' follow-up. However, a small trial that assigned 20 patients with bilateral symptomatic great saphenous vein reflux to laser ablation for one leg and vein stripping for the other leg found that 70 percent of the patients preferred laser ablation [<a href="#rid92">92</a>]. In another trial that compared laser ablation with foam sclerotherapy or surgical stripping, laser ablation was associated with fewer complications and a trend for improved quality of life (eg, primarily prolonged bruising, tenderness, staining, hematoma) [<a href="#rid93">93,94</a>]. Among participants who completed questionnaires at five years (75 percent), disease-specific quality-of-life at five years (Aberdeen Varicose Vein Questionnaire [AVVQ]) was improved compared to baseline for all groups, but was better for laser ablation or surgery compared with foam sclerotherapy [<a href="#rid95">95</a>]. </p><p>Sclerotherapy is also effective in relieving pain in the treated veins with high rates of patient satisfaction [<a href="#rid86">86,96,97</a>]. As a method of eliminating incompetent perforator veins, foam sclerotherapy significantly reduces symptoms and signs as determined by venous clinical scores. In the only available long-term patient series, clinical improvement was sustained at a mean follow-up of 20.1 months [<a href="#rid78">78</a>]. </p><p>It is important to note that improvements in quality of life and patient satisfaction scores do not necessarily mirror closure rates (see <a class="local">'Vein closure'</a> above), with patients reporting satisfaction and relief of symptoms after partial closure or even after recanalization [<a href="#rid16">16,86-88,98,99</a>]. This has been demonstrated in the PEM VANISH trials [<a href="#rid16">16</a>], and also in randomized trials for thermal ablation techniques, one of which showed that only a small fraction of patients with recanalization after any treatment needed repeated treatment for symptoms [<a href="#rid24">24,42,80,90</a>]. In one prospective trial, saphenous vein recanalization occurred in 27 and 64 percent of patients treated with PCF at one and five years, respectively [<a href="#rid87">87</a>]. However, 70 percent of patients did not have recurrent clinical symptoms. Repeat treatment was needed in only 16.5 percent of patients between one and two years, and fewer than 10 percent in subsequent years (up to five years). These consistent data imply that closure of symptomatic varicosities and venules, which is common with any foam preparation due to the ability to fill small lumens, may be a key to symptom relief. </p><p class="headingAnchor" id="H217790409"><span class="h2">Ulcer healing</span><span class="headingEndMark"> — </span>Surgical trials have demonstrated that saphenous stripping reduces ulcer recurrence rates [<a href="#rid100">100-102</a>]. An early trial comparing endovenous ablation with compression therapy likewise demonstrated that patients suffered fewer recurrences following endovenous saphenous vein ablation, but also that ulcers healed faster [<a href="#rid103">103</a>]. </p><p>Persistent reflux in perforating veins following the management of saphenous reflux is a risk factor for venous ulcer nonhealing or recurrence [<a href="#rid100">100,104</a>]. </p><p>Although perforator ablation should not be the first management strategy in the treatment of venous ulcers, there is good evidence that following treatment of axial reflux, treatment of pathologic perforators speeds ulcer healing [<a href="#rid39">39,62,100,104-107</a>]. Healing rates of venous ulcers following foam sclerotherapy appear to be similar to those reported after surgery [<a href="#rid108">108</a>]. In an observational study, ulcer healing was ultimately observed in 32 of 37 limbs treated by foam sclerotherapy [<a href="#rid78">78</a>]. This group of patients did not have concomitant axial vein reflux. More than one treatment session was required due to the development of recurrent perforators in 12 of 37 limbs treated. In another study, 79 percent of active ulcers healed following foam sclerotherapy of associated varicose veins [<a href="#rid109">109</a>]. By contrast, a small trial found healing of venous ulcers in 17/22 patients treated with four-layer compression bandages alone and 12/13 patients treated with compression bandaging plus foam sclerotherapy to incompetent truncal veins, but the difference was not significant [<a href="#rid110">110</a>]. </p><p class="headingAnchor" id="H2036452705"><span class="h2">Patient experience and satisfaction</span><span class="headingEndMark"> — </span>Comparisons between procedural pain scores have not demonstrated clear advantages of the nonthermal techniques over thermal ablation [<a href="#rid12">12</a>]. However, one clear advantage of the nonthermal ablation technique is the avoidance of tumescent anesthesia during the procedure. Not only does this eliminate needle sticks and pressure from the anesthetic infiltration, it expedites the procedure, benefitting both the patient and physician. In addition to avoiding tumescent anesthesia, cyanoacrylate glue sealing does not require compression stockings postprocedurally. This is particularly advantageous to patients who have difficulty tolerating compression. However, in spite of not using tumescence, the VeClose trial (ie, VenaSeal) demonstrated similar intraprocedural pain scores to radiofrequency ablation [<a href="#rid12">12</a>]. Other aspects of the nonthermal ablation procedures may be uncomfortable. Some thin patients are bothered by the agitation and possible valve traction during mechanochemical ablation (MOCA). Pressure held on the vein during cyanoacrylate glue use can be bothersome, and <a class="drug drug_general" data-topicid="9907" href="/z/d/drug information/9907.html" rel="external">polidocanol</a> can be irritating, especially if extravasation occurs. </p><p>The patient experience with laser ablation is very similar to radiofrequency ablation, including tumescence. Multiple randomized trials have shown that immediate postoperative quality-of-life measures (pain, ecchymosis, tenderness) are significantly better following treatment of the saphenous vein using radiofrequency ablation compared with endovenous laser ablation [<a href="#rid22">22,23,91,111-113</a>], although some newer laser wavelengths (eg, 1470 nm) are associated with fewer postoperative symptoms [<a href="#rid114">114</a>]. Pain and ecchymosis remain the dominant complaints associated with laser ablation and likely correlate with microperforations occurring along the vein wall, related to thermal injury. </p><p>The time to return to normal activities or return to work is variable among the available clinical trials [<a href="#rid22">22,23,41</a>]. The low incidence of adverse effects and complications with radiofrequency ablation results in a significantly lower number of days to return to normal activities and work compared with vein stripping (1.5 versus 3.9 days, 4.7 versus 12.4 days) [<a href="#rid22">22,23</a>]. Similarly, in a trial of 99 patients, time to return to normal activity and return to work was decreased for laser ablation compared with great saphenous vein ligation and stripping (2 versus 7 days and 4 versus 17 days, respectively) [<a href="#rid41">41</a>]. On the other hand, two trials involving 200 and 121 patients found no significant differences in return to normal activity or work for laser ablation compared with surgical stripping (average, 7 days) [<a href="#rid90">90,115</a>]. In another trial, the time to return to work was longer for laser ablation compared with great saphenous vein ligation and stripping (20 versus 14 days) [<a href="#rid40">40</a>]. </p><p>In a study comparing radiofrequency ablation and cyanoacrylate, despite similar efficacy and a higher rate of postprocedural thrombophlebitis in cyanoacrylate-treated patients, patients were able to return to work significantly more quickly compared with radiofrequency ablation-treated patients [<a href="#rid116">116</a>].</p><p>Similar results have been noted for small saphenous vein laser ablation. In a trial comparing small saphenous laser ablation with surgery, significantly less postoperative pain occurred after laser ablation allowing an earlier return to work and normal function [<a href="#rid117">117</a>]. Fewer minor sensory disturbances occurred in those who underwent laser ablation compared with surgery (7.5 versus 26.4 percent). However, both groups demonstrated similar improvements in Venous Clinical Severity Score and quality of life.</p><p class="headingAnchor" id="H3816580907"><span class="h2">Complications</span><span class="headingEndMark"> — </span>Complications from endovenous ablation are uncommon and usually straightforward to manage. Although there are many studies that report complication rates with the different techniques  (<a class="graphic graphic_table graphicRef120622" href="/z/d/graphic/120622.html" rel="external">table 4</a>), there are few clear differences. Sclerotherapy is associated with unique complications that are generally preventable using optimal techniques. Nerve injury is increased for thermal compared with non-thermal techniques. (See  <a class="medical medical_review" href="/z/d/html/8203.html" rel="external">"Techniques for radiofrequency ablation for the treatment of lower extremity chronic venous disease", section on 'Complications'</a> and  <a class="medical medical_review" href="/z/d/html/15198.html" rel="external">"Techniques for endovenous laser ablation for the treatment of lower extremity chronic venous disease", section on 'Complications'</a>.)</p><p class="headingAnchor" id="H2665043764"><span class="h2">Cost</span><span class="headingEndMark"> — </span>Cost analysis of minimally invasive venous ablation methods have varied [<a href="#rid118">118</a>]. Reimbursement for venous procedures is an ever-shifting landscape. Depending on the proportion of cash-pay versus insurance and other local factors, a private office may not be able to offer every technique. </p><p>The most cost-effective method for an interventionalist is likely bare-tipped laser as these can be used with a one-time generator purchase, lease, or gift from the catheter manufacturer. Fibers are generally inexpensive, and some can have the tip cut off and the remaining catheter re-sterilized and reused up to four additional times. The supplies for nonthermal techniques are generally more expensive to purchase. An exception is physician-compounded foam (PCF), which is very inexpensive, especially if the sclerosant is purchased from a compounding pharmacy. </p><p>One trial evaluated differences in cost between laser ablation and ligation and stripping of the great saphenous vein and found no significant differences between these procedures [<a href="#rid90">90</a>]. Another trial used a Markov model to estimate costs of foam sclerotherapy, laser ablation, and surgical stripping. Costs were significantly decreased for laser ablation compared with surgical stripping but were more than sclerotherapy [<a href="#rid93">93</a>]. However, because of overall greater improvements in health-related quality of life, laser ablation was judged to be the more cost-effective treatment. </p><p class="headingAnchor" id="H2786919625"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118466.html" rel="external">"Society guideline links: Chronic venous disorders"</a>.)</p><p class="headingAnchor" id="H827707150"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/87610.html" rel="external">"Patient education: Vein ablation (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2426295458"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Venous ablation</strong> – Vein closure (ablation) is appropriate for patients with persistent symptoms or cosmetic concerns related to venous reflux in the great, small, or anterior saphenous veins, collectively known as the axial veins. Endovenous ablation techniques, rather than open surgical ligation and stripping, are recommended as the primary method of treating symptomatic reflux in these veins. (See <a class="local">'Introduction'</a> above and  <a class="medical medical_review" href="/z/d/html/8181.html" rel="external">"Overview of lower extremity chronic venous disease", section on 'Management'</a> and  <a class="medical medical_review" href="/z/d/html/121344.html" rel="external">"Approach to treating symptomatic superficial venous insufficiency", section on 'Technique selection by axial vein'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Techniques</strong> – Techniques for endovenous ablation include thermal (radiofrequency ablation, laser ablation) and nonthermal (<a class="drug drug_general" data-topicid="9907" href="/z/d/drug information/9907.html" rel="external">polidocanol</a> endovenous microfoam [PEM], endovenous mechanochemical ablation [MOCA], and cyanoacrylate) techniques. Each method of vein ablation has unique characteristics  (<a class="graphic graphic_table graphicRef119312" href="/z/d/graphic/119312.html" rel="external">table 1</a>). (See <a class="local">'Technique summary'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes comparisons</strong> – Understanding the technical differences and the advantages and disadvantages of each technique helps to create an individualized treatment plan and helps to provide comprehensive care for patients with chronic venous disease. All methods of endovenous ablation have high initial technical success rates  (<a class="graphic graphic_table graphicRef119311" href="/z/d/graphic/119311.html" rel="external">table 3</a>). Recanalization of the treated vein is most likely to occur with foam sclerotherapy. The rate of new vein formation is similar for all methods. It is important to note that clinical success as measured by quality of life and patient satisfaction scores often persists in spite of less than complete closure with initial treatment, later recanalization of the treated veins, or new vein formation. (See <a class="local">'Outcome comparisons'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – The overall complication rates for endovenous ablation are low  (<a class="graphic graphic_table graphicRef120622" href="/z/d/graphic/120622.html" rel="external">table 4</a>). The types of complications are similar; however, sclerotherapy is associated with unique complications that are generally preventable using optimal techniques. Nerve injury is increased for thermal compared with non-thermal techniques. (See <a class="local">'Complications'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Min RJ, Khilnani N, Zimmet SE. Endovenous laser treatment of saphenous vein reflux: long-term results. J Vasc Interv Radiol 2003; 14:991.</a></li><li><a class="nounderline abstract_t">Timperman PE, Sichlau M, Ryu RK. Greater energy delivery improves treatment success of endovenous laser treatment of incompetent saphenous veins. J Vasc Interv Radiol 2004; 15:1061.</a></li><li><a class="nounderline abstract_t">Timperman PE. Prospective evaluation of higher energy great saphenous vein endovenous laser treatment. J Vasc Interv Radiol 2005; 16:791.</a></li><li><a class="nounderline abstract_t">Pannier F, Rabe E, Maurins U. First results with a new 1470-nm diode laser for endovenous ablation of incompetent saphenous veins. Phlebology 2009; 24:26.</a></li><li><a class="nounderline abstract_t">Malskat WS, Giang J, De Maeseneer MG, et al. Randomized clinical trial of 940- versus 1470-nm endovenous laser ablation for great saphenous vein incompetence. Br J Surg 2016; 103:192.</a></li><li><a class="nounderline abstract_t">Mackay EG, Almeida JI, Raines JK. Do different laser wavelengths translate into different patient experiences? Endovasc Today 2006; 45.</a></li><li><a class="nounderline abstract_t">Kabnick LS. Outcome of different endovenous laser wavelengths for great saphenous vein ablation. J Vasc Surg 2006; 43:88.</a></li><li><a class="nounderline abstract_t">Proebstle TM, Moehler T, Gül D, Herdemann S. Endovenous treatment of the great saphenous vein using a 1,320 nm Nd:YAG laser causes fewer side effects than using a 940 nm diode laser. Dermatol Surg 2005; 31:1678.</a></li><li><a class="nounderline abstract_t">Shutze WP, Kane K, Fisher T, et al. The effect of wavelength on endothermal heat-induced thrombosis incidence after endovenous laser ablation. J Vasc Surg Venous Lymphat Disord 2016; 4:36.</a></li><li><a class="nounderline abstract_t">Maurins U, Rabe E, Pannier F. Does laser power influence the results of endovenous laser ablation (EVLA) of incompetent saphenous veins with the 1 470-nm diode laser? A prospective randomized study comparing 15 and 25 W. Int Angiol 2009; 28:32.</a></li><li><a class="nounderline abstract_t">Kabnick LS, Sadek M. Fiber type as compared to wavelength may contribute more to improving postoperative recovery following endovenous laser ablation. J Vasc Surg Venous Lymphat Disord 2016; 4:286.</a></li><li><a class="nounderline abstract_t">Morrison N, Gibson K, McEnroe S, et al. Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous veins (VeClose). J Vasc Surg 2015; 61:985.</a></li><li><a class="nounderline abstract_t">Proebstle TM, Vago B, Alm J, et al. Treatment of the incompetent great saphenous vein by endovenous radiofrequency powered segmental thermal ablation: first clinical experience. J Vasc Surg 2008; 47:151.</a></li><li><a class="nounderline abstract_t">Min RJ, Zimmet SE, Isaacs MN, Forrestal MD. Endovenous laser treatment of the incompetent greater saphenous vein. J Vasc Interv Radiol 2001; 12:1167.</a></li><li><a class="nounderline abstract_t">King JT, O'Byrne M, Vasquez M, et al. Treatment of Truncal Incompetence and Varicose Veins with a Single Administration of a New Polidocanol Endovenous Microfoam Preparation Improves Symptoms and Appearance. Eur J Vasc Endovasc Surg 2015; 50:784.</a></li><li><a class="nounderline abstract_t">Todd KL 3rd, Wright DI, VANISH-2 Investigator Group. The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology 2014; 29:608.</a></li><li><a class="nounderline abstract_t">Elias S, Raines JK. Mechanochemical tumescentless endovenous ablation: final results of the initial clinical trial. Phlebology 2012; 27:67.</a></li><li><a class="nounderline abstract_t">Pan Y, Zhao J, Mei J, et al. Comparison of endovenous laser ablation and high ligation and stripping for varicose vein treatment: a meta-analysis. Phlebology 2014; 29:109.</a></li><li><a class="nounderline abstract_t">Carroll C, Hummel S, Leaviss J, et al. Systematic review, network meta-analysis and exploratory cost-effectiveness model of randomized trials of minimally invasive techniques versus surgery for varicose veins. Br J Surg 2014; 101:1040.</a></li><li><a class="nounderline abstract_t">Nesbitt C, Bedenis R, Bhattacharya V, Stansby G. Endovenous ablation (radiofrequency and laser) and foam sclerotherapy versus open surgery for great saphenous vein varices. Cochrane Database Syst Rev 2014; :CD005624.</a></li><li><a class="nounderline abstract_t">Lurie F, Creton D, Eklof B, et al. Prospective randomised study of endovenous radiofrequency obliteration (closure) versus ligation and vein stripping (EVOLVeS): two-year follow-up. Eur J Vasc Endovasc Surg 2005; 29:67.</a></li><li><a class="nounderline abstract_t">Lurie F, Creton D, Eklof B, et al. Prospective randomized study of endovenous radiofrequency obliteration (closure procedure) versus ligation and stripping in a selected patient population (EVOLVeS Study). J Vasc Surg 2003; 38:207.</a></li><li><a class="nounderline abstract_t">Almeida JI, Kaufman J, Göckeritz O, et al. Radiofrequency endovenous ClosureFAST versus laser ablation for the treatment of great saphenous reflux: a multicenter, single-blinded, randomized study (RECOVERY study). J Vasc Interv Radiol 2009; 20:752.</a></li><li><a class="nounderline abstract_t">Rasmussen LH, Lawaetz M, Bjoern L, et al. Randomized clinical trial comparing endovenous laser ablation, radiofrequency ablation, foam sclerotherapy and surgical stripping for great saphenous varicose veins. Br J Surg 2011; 98:1079.</a></li><li><a class="nounderline abstract_t">Van Den Bos RR, Neumann M, De Roos KP, Nijsten T. Endovenous laser ablation-induced complications: review of the literature and new cases. Dermatol Surg 2009; 35:1206.</a></li><li><a class="nounderline abstract_t">Proebstle TM, Alm BJ, Göckeritz O, et al. Five-year results from the prospective European multicentre cohort study on radiofrequency segmental thermal ablation for incompetent great saphenous veins. Br J Surg 2015; 102:212.</a></li><li><a class="nounderline abstract_t">Proebstle TM, Alm J, Göckeritz O, et al. Three-year European follow-up of endovenous radiofrequency-powered segmental thermal ablation of the great saphenous vein with or without treatment of calf varicosities. J Vasc Surg 2011; 54:146.</a></li><li><a class="nounderline abstract_t">Spreafico G, Kabnick L, Berland TL, et al. Laser saphenous ablations in more than 1,000 limbs with long-term duplex examination follow-up. Ann Vasc Surg 2011; 25:71.</a></li><li><a class="nounderline abstract_t">Hamann SAS, Timmer-de Mik L, Fritschy WM, et al. Randomized clinical trial of endovenous laser ablation versus direct and indirect radiofrequency ablation for the treatment of great saphenous varicose veins. Br J Surg 2019; 106:998.</a></li><li><a class="nounderline abstract_t">Leung CC, Carradice D, Wallace T, Chetter IC. Endovenous laser ablation versus mechanochemical ablation with ClariVein(®) in the management of superficial venous insufficiency (LAMA trial): study protocol for a randomised controlled trial. Trials 2016; 17:421.</a></li><li><a class="nounderline abstract_t">van Eekeren RR, Boersma D, Konijn V, et al. Postoperative pain and early quality of life after radiofrequency ablation and mechanochemical endovenous ablation of incompetent great saphenous veins. J Vasc Surg 2013; 57:445.</a></li><li><a class="nounderline abstract_t">van Eekeren RR, Boersma D, Holewijn S, et al. Mechanochemical endovenous Ablation versus RADiOfrequeNcy Ablation in the treatment of primary great saphenous vein incompetence (MARADONA): study protocol for a randomized controlled trial. Trials 2014; 15:121.</a></li><li><a class="nounderline abstract_t">Bootun R, Lane TR, Dharmarajah B, et al. Intra-procedural pain score in a randomised controlled trial comparing mechanochemical ablation to radiofrequency ablation: The Multicentre Venefit™ versus ClariVein® for varicose veins trial. Phlebology 2016; 31:61.</a></li><li><a class="nounderline abstract_t">Luebke T, Brunkwall J. Systematic review and meta-analysis of endovenous radiofrequency obliteration, endovenous laser therapy, and foam sclerotherapy for primary varicosis. J Cardiovasc Surg (Torino) 2008; 49:213.</a></li><li><a class="nounderline abstract_t">van den Bos R, Arends L, Kockaert M, et al. Endovenous therapies of lower extremity varicosities: a meta-analysis. J Vasc Surg 2009; 49:230.</a></li><li><a class="nounderline abstract_t">Perälä J, Rautio T, Biancari F, et al. Radiofrequency endovenous obliteration versus stripping of the long saphenous vein in the management of primary varicose veins: 3-year outcome of a randomized study. Ann Vasc Surg 2005; 19:669.</a></li><li><a class="nounderline abstract_t">Peden E, Lumsden A. Radiofrequency ablation of incompetent perforator veins. Perspect Vasc Surg Endovasc Ther 2007; 19:73.</a></li><li><a class="nounderline abstract_t">van Rij AM, Hill G, Gray C, et al. A prospective study of the fate of venous leg perforators after varicose vein surgery. J Vasc Surg 2005; 42:1156.</a></li><li><a class="nounderline abstract_t">Bacon JL, Dinneen AJ, Marsh P, et al. Five-year results of incompetent perforator vein closure using TRans-Luminal Occlusion of Perforator. Phlebology 2009; 24:74.</a></li><li><a class="nounderline abstract_t">Kalteis M, Berger I, Messie-Werndl S, et al. High ligation combined with stripping and endovenous laser ablation of the great saphenous vein: early results of a randomized controlled study. J Vasc Surg 2008; 47:822.</a></li><li><a class="nounderline abstract_t">Darwood RJ, Theivacumar N, Dellagrammaticas D, et al. Randomized clinical trial comparing endovenous laser ablation with surgery for the treatment of primary great saphenous varicose veins. Br J Surg 2008; 95:294.</a></li><li><a class="nounderline abstract_t">Rasmussen LH, Bjoern L, Lawaetz M, et al. Randomised clinical trial comparing endovenous laser ablation with stripping of the great saphenous vein: clinical outcome and recurrence after 2 years. Eur J Vasc Endovasc Surg 2010; 39:630.</a></li><li><a class="nounderline abstract_t">Ravi R, Rodriguez-Lopez JA, Trayler EA, et al. Endovenous ablation of incompetent saphenous veins: a large single-center experience. J Endovasc Ther 2006; 13:244.</a></li><li><a class="nounderline abstract_t">Agus GB, Mancini S, Magi G, IEWG. The first 1000 cases of Italian Endovenous-laser Working Group (IEWG). Rationale, and long-term outcomes for the 1999-2003 period. Int Angiol 2006; 25:209.</a></li><li><a class="nounderline abstract_t">Desmyttère J, Grard C, Wassmer B, Mordon S. Endovenous 980-nm laser treatment of saphenous veins in a series of 500 patients. J Vasc Surg 2007; 46:1242.</a></li><li><a class="nounderline abstract_t">Kim HS, Paxton BE. Endovenous laser ablation of the great saphenous vein with a 980-nm diode laser in continuous mode: early treatment failures and successful repeat treatments. J Vasc Interv Radiol 2006; 17:1449.</a></li><li><a class="nounderline abstract_t">Chaar CI, Hirsch SA, Cwenar MT, et al. Expanding the role of endovenous laser therapy: results in large diameter saphenous, small saphenous, and anterior accessory veins. Ann Vasc Surg 2011; 25:656.</a></li><li><a class="nounderline abstract_t">Florescu C, Curry G, Buckenham T. Role of endovenous laser therapy in large and very large diameter great saphenous veins. ANZ J Surg 2016; 86:608.</a></li><li><a class="nounderline abstract_t">Atasoy MM. Efficacy and Safety of Endovenous Laser Ablation in Very Large and Tortuous Great Saphenous Veins. J Vasc Interv Radiol 2015; 26:1347.</a></li><li><a class="nounderline abstract_t">Starodubtsev V, Lukyanenko M, Karpenko A, Ignatenko P. Endovenous laser ablation in patients with wide diameter of the proximal segment of the great saphenous vein: Comparison of methods. Phlebology 2015; 30:700.</a></li><li><a class="nounderline abstract_t">Bush RG, Hammond K. Treatment of incompetent vein of Giacomini (thigh extension branch). Ann Vasc Surg 2007; 21:245.</a></li><li><a class="nounderline abstract_t">Theivacumar NS, Dellagrammaticas D, Mavor AI, Gough MJ. Endovenous laser ablation (EVLA) of great saphenous vein to abolish "paradoxical reflux" in the Giacomini vein: a short report. Eur J Vasc Endovasc Surg 2007; 34:229.</a></li><li><a class="nounderline abstract_t">Ravi R, Trayler EA, Barrett DA, Diethrich EB. Endovenous thermal ablation of superficial venous insufficiency of the lower extremity: single-center experience with 3000 limbs treated in a 7-year period. J Endovasc Ther 2009; 16:500.</a></li><li><a class="nounderline abstract_t">Nwaejike N, Srodon PD, Kyriakides C. Endovenous laser ablation for short saphenous vein incompetence. Ann Vasc Surg 2009; 23:39.</a></li><li><a class="nounderline abstract_t">Trip-Hoving M, Verheul JC, van Sterkenburg SM, et al. Endovenous laser therapy of the small saphenous vein: patient satisfaction and short-term results. Photomed Laser Surg 2009; 27:655.</a></li><li><a class="nounderline abstract_t">Theivacumar NS, Darwood RJ, Gough MJ. Endovenous laser ablation (EVLA) of the anterior accessory great saphenous vein (AAGSV): abolition of sapheno-femoral reflux with preservation of the great saphenous vein. Eur J Vasc Endovasc Surg 2009; 37:477.</a></li><li><a class="nounderline abstract_t">Kontothanassis D, Di Mitri R, Ferrari Ruffino S, et al. Endovenous laser treatment of the small saphenous vein. J Vasc Surg 2009; 49:973.</a></li><li><a class="nounderline abstract_t">Monahan TS, Belek K, Sarkar R. Results of radiofrequency ablation of the small saphenous vein in the supine position. Vasc Endovascular Surg 2012; 46:40.</a></li><li><a class="nounderline abstract_t">She W, Dai Y, Du X, et al. Hearing evaluation of intratympanic methylprednisolone perfusion for refractory sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 2010; 142:266.</a></li><li class="breakAll">Adelman M. The SECURE Trial: Update on Perforator Ablation. VEITH. New York, NY 2018.</li><li><a class="nounderline abstract_t">Lawrence PF, Alktaifi A, Rigberg D, et al. Endovenous ablation of incompetent perforating veins is effective treatment for recalcitrant venous ulcers. J Vasc Surg 2011; 54:737.</a></li><li><a class="nounderline abstract_t">Kiguchi MM, Hager ES, Winger DG, et al. Factors that influence perforator thrombosis and predict healing with perforator sclerotherapy for venous ulceration without axial reflux. J Vasc Surg 2014; 59:1368.</a></li><li><a class="nounderline abstract_t">Wittens C, Davies AH, Bækgaard N, et al. Editor's Choice - Management of Chronic Venous Disease: Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 2015; 49:678.</a></li><li><a class="nounderline abstract_t">Gonzalez-Zeh R, Armisen R, Barahona S. Endovenous laser and echo-guided foam ablation in great saphenous vein reflux: one-year follow-up results. J Vasc Surg 2008; 48:940.</a></li><li><a class="nounderline abstract_t">Weiss RA, Munavalli G. Endovenous ablation of truncal veins. Semin Cutan Med Surg 2005; 24:193.</a></li><li><a class="nounderline abstract_t">Goldman MP. Intravascular lasers in the treatment of varicose veins. J Cosmet Dermatol 2004; 3:162.</a></li><li><a class="nounderline abstract_t">Shadid N, Nelemans P, Lawson J, Sommer A. Predictors of recurrence of great saphenous vein reflux following treatment with ultrasound-guided foamsclerotherapy. Phlebology 2015; 30:194.</a></li><li><a class="nounderline abstract_t">Davies HO, Popplewell M, Darvall K, et al. A review of randomised controlled trials comparing ultrasound-guided foam sclerotherapy with endothermal ablation for the treatment of great saphenous varicose veins. Phlebology 2016; 31:234.</a></li><li><a class="nounderline abstract_t">Neglén P, Einarsson E, Eklöf B. The functional long-term value of different types of treatment for saphenous vein incompetence. J Cardiovasc Surg (Torino) 1993; 34:295.</a></li><li><a class="nounderline abstract_t">Belcaro G, Nicolaides AN, Ricci A, et al. Endovascular sclerotherapy, surgery, and surgery plus sclerotherapy in superficial venous incompetence: a randomized, 10-year follow-up trial--final results. Angiology 2000; 51:529.</a></li><li><a class="nounderline abstract_t">Belcaro G, Cesarone MR, Di Renzo A, et al. Foam-sclerotherapy, surgery, sclerotherapy, and combined treatment for varicose veins: a 10-year, prospective, randomized, controlled, trial (VEDICO trial). Angiology 2003; 54:307.</a></li><li><a class="nounderline abstract_t">Rigby KA, Palfreyman SJ, Beverley C, Michaels JA. Surgery versus sclerotherapy for the treatment of varicose veins. Cochrane Database Syst Rev 2004; :CD004980.</a></li><li><a class="nounderline abstract_t">Chen CH, Chiu CS, Yang CH. Ultrasound-guided foam sclerotherapy for treating incompetent great saphenous veins--results of 5 years of analysis and morphologic evolvement study. Dermatol Surg 2012; 38:851.</a></li><li><a class="nounderline abstract_t">Barrett JM, Allen B, Ockelford A, Goldman MP. Microfoam ultrasound-guided sclerotherapy of varicose veins in 100 legs. Dermatol Surg 2004; 30:6.</a></li><li><a class="nounderline abstract_t">Darvall KA, Bate GR, Adam DJ, et al. Duplex ultrasound outcomes following ultrasound-guided foam sclerotherapy of symptomatic primary great saphenous varicose veins. Eur J Vasc Endovasc Surg 2010; 40:534.</a></li><li><a class="nounderline abstract_t">Darvall KA, Bate GR, Silverman SH, et al. Medium-term results of ultrasound-guided foam sclerotherapy for small saphenous varicose veins. Br J Surg 2009; 96:1268.</a></li><li><a class="nounderline abstract_t">Boersma D, van Eekeren RR, Werson DA, et al. Mechanochemical endovenous ablation of small saphenous vein insufficiency using the ClariVein(®) device: one-year results of a prospective series. Eur J Vasc Endovasc Surg 2013; 45:299.</a></li><li><a class="nounderline abstract_t">Masuda EM, Kessler DM, Lurie F, et al. The effect of ultrasound-guided sclerotherapy of incompetent perforator veins on venous clinical severity and disability scores. J Vasc Surg 2006; 43:551.</a></li><li><a class="nounderline abstract_t">Dillavou ED, Harlander-Locke M, Labropoulos N, et al. Current state of the treatment of perforating veins. J Vasc Surg Venous Lymphat Disord 2016; 4:131.</a></li><li><a class="nounderline abstract_t">Rasmussen L, Lawaetz M, Bjoern L, et al. Randomized clinical trial comparing endovenous laser ablation and stripping of the great saphenous vein with clinical and duplex outcome after 5 years. J Vasc Surg 2013; 58:421.</a></li><li><a class="nounderline abstract_t">Flessenkämper I, Hartmann M, Hartmann K, et al. Endovenous laser ablation with and without high ligation compared to high ligation and stripping for treatment of great saphenous varicose veins: Results of a multicentre randomised controlled trial with up to 6 years follow-up. Phlebology 2016; 31:23.</a></li><li><a class="nounderline abstract_t">Carradice D, Mekako AI, Mazari FA, et al. Clinical and technical outcomes from a randomized clinical trial of endovenous laser ablation compared with conventional surgery for great saphenous varicose veins. Br J Surg 2011; 98:1117.</a></li><li><a class="nounderline abstract_t">Gauw SA, Lawson JA, van Vlijmen-van Keulen CJ, et al. Five-year follow-up of a randomized, controlled trial comparing saphenofemoral ligation and stripping of the great saphenous vein with endovenous laser ablation (980 nm) using local tumescent anesthesia. J Vasc Surg 2016; 63:420.</a></li><li><a class="nounderline abstract_t">Rass K, Frings N, Glowacki P, et al. Comparable effectiveness of endovenous laser ablation and high ligation with stripping of the great saphenous vein: two-year results of a randomized clinical trial (RELACS study). Arch Dermatol 2012; 148:49.</a></li><li><a class="nounderline abstract_t">Jia X, Mowatt G, Burr JM, et al. Systematic review of foam sclerotherapy for varicose veins. Br J Surg 2007; 94:925.</a></li><li><a class="nounderline abstract_t">Tisi PV, Beverley C, Rees A. Injection sclerotherapy for varicose veins. Cochrane Database Syst Rev 2006; :CD001732.</a></li><li><a class="nounderline abstract_t">Chapman-Smith P, Browne A. Prospective five-year study of ultrasound-guided foam sclerotherapy in the treatment of great saphenous vein reflux. Phlebology 2009; 24:183.</a></li><li><a class="nounderline abstract_t">Hamel-Desnos C, Desnos P, Wollmann JC, et al. Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatol Surg 2003; 29:1170.</a></li><li><a class="nounderline abstract_t">Carradice D, Mekako AI, Mazari FA, et al. Randomized clinical trial of endovenous laser ablation compared with conventional surgery for great saphenous varicose veins. Br J Surg 2011; 98:501.</a></li><li><a class="nounderline abstract_t">Rasmussen LH, Bjoern L, Lawaetz M, et al. Randomized trial comparing endovenous laser ablation of the great saphenous vein with high ligation and stripping in patients with varicose veins: short-term results. J Vasc Surg 2007; 46:308.</a></li><li><a class="nounderline abstract_t">Shepherd AC, Gohel MS, Brown LC, et al. Randomized clinical trial of VNUS ClosureFAST radiofrequency ablation versus laser for varicose veins. Br J Surg 2010; 97:810.</a></li><li><a class="nounderline abstract_t">de Medeiros CA, Luccas GC. Comparison of endovenous treatment with an 810 nm laser versus conventional stripping of the great saphenous vein in patients with primary varicose veins. Dermatol Surg 2005; 31:1685.</a></li><li><a class="nounderline abstract_t">Tassie E, Scotland G, Brittenden J, et al. Cost-effectiveness of ultrasound-guided foam sclerotherapy, endovenous laser ablation or surgery as treatment for primary varicose veins from the randomized CLASS trial. Br J Surg 2014; 101:1532.</a></li><li><a class="nounderline abstract_t">Brittenden J, Cotton SC, Elders A, et al. A randomized trial comparing treatments for varicose veins. N Engl J Med 2014; 371:1218.</a></li><li><a class="nounderline abstract_t">Brittenden J, Cooper D, Dimitrova M, et al. Five-Year Outcomes of a Randomized Trial of Treatments for Varicose Veins. N Engl J Med 2019; 381:912.</a></li><li><a class="nounderline abstract_t">Labas P, Ohradka B, Cambal M, et al. Long term results of compression sclerotherapy. Bratisl Lek Listy 2003; 104:78.</a></li><li><a class="nounderline abstract_t">Weiss RA, Weiss MA. Resolution of pain associated with varicose and telangiectatic leg veins after compression sclerotherapy. J Dermatol Surg Oncol 1990; 16:333.</a></li><li><a class="nounderline abstract_t">Merchant RF, Pichot O, Closure Study Group. Long-term outcomes of endovenous radiofrequency obliteration of saphenous reflux as a treatment for superficial venous insufficiency. J Vasc Surg 2005; 42:502.</a></li><li><a class="nounderline abstract_t">Merchant RF, DePalma RG, Kabnick LS. Endovascular obliteration of saphenous reflux: a multicenter study. J Vasc Surg 2002; 35:1190.</a></li><li><a class="nounderline abstract_t">O'Donnell TF Jr. The present status of surgery of the superficial venous system in the management of venous ulcer and the evidence for the role of perforator interruption. J Vasc Surg 2008; 48:1044.</a></li><li><a class="nounderline abstract_t">Stuart WP, Adam DJ, Allan PL, et al. Saphenous surgery does not correct perforator incompetence in the presence of deep venous reflux. J Vasc Surg 1998; 28:834.</a></li><li><a class="nounderline abstract_t">Kianifard B, Holdstock J, Allen C, et al. Randomized clinical trial of the effect of adding subfascial endoscopic perforator surgery to standard great saphenous vein stripping. Br J Surg 2007; 94:1075.</a></li><li><a class="nounderline abstract_t">Gohel MS, Heatley F, Liu X, et al. A Randomized Trial of Early Endovenous Ablation in Venous Ulceration. N Engl J Med 2018; 378:2105.</a></li><li><a class="nounderline abstract_t">Tenbrook JA Jr, Iafrati MD, O'donnell TF Jr, et al. Systematic review of outcomes after surgical management of venous disease incorporating subfascial endoscopic perforator surgery. J Vasc Surg 2004; 39:583.</a></li><li><a class="nounderline abstract_t">Harlander-Locke M, Lawrence PF, Alktaifi A, et al. The impact of ablation of incompetent superficial and perforator veins on ulcer healing rates. J Vasc Surg 2012; 55:458.</a></li><li><a class="nounderline abstract_t">van den Bos RR, Wentel T, Neumann MH, Nijsten T. Treatment of incompetent perforating veins using the radiofrequency ablation stylet: a pilot study. Phlebology 2009; 24:208.</a></li><li><a class="nounderline abstract_t">Marrocco CJ, Atkins MD, Bohannon WT, et al. Endovenous ablation for the treatment of chronic venous insufficiency and venous ulcerations. World J Surg 2010; 34:2299.</a></li><li><a class="nounderline abstract_t">Pang KH, Bate GR, Darvall KA, et al. Healing and recurrence rates following ultrasound-guided foam sclerotherapy of superficial venous reflux in patients with chronic venous ulceration. Eur J Vasc Endovasc Surg 2010; 40:790.</a></li><li><a class="nounderline abstract_t">Nael R, Rathbun S. Effectiveness of foam sclerotherapy for the treatment of varicose veins. Vasc Med 2010; 15:27.</a></li><li><a class="nounderline abstract_t">O'Hare JL, Earnshaw JJ. Randomised clinical trial of foam sclerotherapy for patients with a venous leg ulcer. Eur J Vasc Endovasc Surg 2010; 39:495.</a></li><li><a class="nounderline abstract_t">Goode SD, Chowdhury A, Crockett M, et al. Laser and radiofrequency ablation study (LARA study): a randomised study comparing radiofrequency ablation and endovenous laser ablation (810 nm). Eur J Vasc Endovasc Surg 2010; 40:246.</a></li><li><a class="nounderline abstract_t">Gale SS, Lee JN, Walsh ME, et al. A randomized, controlled trial of endovenous thermal ablation using the 810-nm wavelength laser and the ClosurePLUS radiofrequency ablation methods for superficial venous insufficiency of the great saphenous vein. J Vasc Surg 2010; 52:645.</a></li><li><a class="nounderline abstract_t">Nordon IM, Hinchliffe RJ, Brar R, et al. A prospective double-blind randomized controlled trial of radiofrequency versus laser treatment of the great saphenous vein in patients with varicose veins. Ann Surg 2011; 254:876.</a></li><li><a class="nounderline abstract_t">Almeida J, Mackay E, Javier J, et al. Saphenous laser ablation at 1470 nm targets the vein wall, not blood. Vasc Endovascular Surg 2009; 43:467.</a></li><li><a class="nounderline abstract_t">Christenson JT, Gueddi S, Gemayel G, Bounameaux H. Prospective randomized trial comparing endovenous laser ablation and surgery for treatment of primary great saphenous varicose veins with a 2-year follow-up. J Vasc Surg 2010; 52:1234.</a></li><li><a class="nounderline abstract_t">From the American Association of Neurological Surgeons (AANS), American Society of Neuroradiology (ASNR), Cardiovascular and Interventional Radiology Society of Europe (CIRSE), Canadian Interventional Radiology Association (CIRA), Congress of Neurological Surgeons (CNS), European Society of Minimally Invasive Neurological Therapy (ESMINT), European Society of Neuroradiology (ESNR), European Stroke Organization (ESO), Society for Cardiovascular Angiography and Interventions (SCAI), Society of Interventional Radiology (SIR), Society of NeuroInterventional Surgery (SNIS), and World Stroke Organization (WSO), Sacks D, Baxter B, et al. Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke. Int J Stroke 2018; 13:612.</a></li><li><a class="nounderline abstract_t">Samuel N, Carradice D, Wallace T, et al. Randomized clinical trial of endovenous laser ablation versus conventional surgery for small saphenous varicose veins. Ann Surg 2013; 257:419.</a></li><li><a class="nounderline abstract_t">Rautio T, Ohinmaa A, Perälä J, et al. Endovenous obliteration versus conventional stripping operation in the treatment of primary varicose veins: a randomized controlled trial with comparison of the costs. J Vasc Surg 2002; 35:958.</a></li></ol></div><div id="topicVersionRevision">Topic 15233 Version 10.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12902556" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Endovenous laser treatment of saphenous vein reflux: long-term results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15466791" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Greater energy delivery improves treatment success of endovenous laser treatment of incompetent saphenous veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15947042" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prospective evaluation of higher energy great saphenous vein endovenous laser treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19155338" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : First results with a new 1470-nm diode laser for endovenous ablation of incompetent saphenous veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26661521" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Randomized clinical trial of 940- versus 1470-nm endovenous laser ablation for great saphenous vein incompetence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Do different laser wavelengths translate into different patient experiences?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16414394" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Outcome of different endovenous laser wavelengths for great saphenous vein ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16336887" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Endovenous treatment of the great saphenous vein using a 1,320 nm Nd:YAG laser causes fewer side effects than using a 940 nm diode laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26946893" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The effect of wavelength on endothermal heat-induced thrombosis incidence after endovenous laser ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19190553" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Does laser power influence the results of endovenous laser ablation (EVLA) of incompetent saphenous veins with the 1 470-nm diode laser? A prospective randomized study comparing 15 and 25 W.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27318047" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Fiber type as compared to wavelength may contribute more to improving postoperative recovery following endovenous laser ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25650040" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous veins (VeClose).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18178468" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Treatment of the incompetent great saphenous vein by endovenous radiofrequency powered segmental thermal ablation: first clinical experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11585882" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Endovenous laser treatment of the incompetent greater saphenous vein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26384639" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Treatment of Truncal Incompetence and Varicose Veins with a Single Administration of a New Polidocanol Endovenous Microfoam Preparation Improves Symptoms and Appearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23864535" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21803800" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Mechanochemical tumescentless endovenous ablation: final results of the initial clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23390218" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Comparison of endovenous laser ablation and high ligation and stripping for varicose vein treatment: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24964976" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Systematic review, network meta-analysis and exploratory cost-effectiveness model of randomized trials of minimally invasive techniques versus surgery for varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25075589" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Endovenous ablation (radiofrequency and laser) and foam sclerotherapy versus open surgery for great saphenous vein varices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15570274" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Prospective randomised study of endovenous radiofrequency obliteration (closure) versus ligation and vein stripping (EVOLVeS): two-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12891099" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Prospective randomized study of endovenous radiofrequency obliteration (closure procedure) versus ligation and stripping in a selected patient population (EVOLVeS Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19395275" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Radiofrequency endovenous ClosureFAST versus laser ablation for the treatment of great saphenous reflux: a multicenter, single-blinded, randomized study (RECOVERY study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21725957" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Randomized clinical trial comparing endovenous laser ablation, radiofrequency ablation, foam sclerotherapy and surgical stripping for great saphenous varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19469796" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Endovenous laser ablation-induced complications: review of the literature and new cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25627262" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Five-year results from the prospective European multicentre cohort study on radiofrequency segmental thermal ablation for incompetent great saphenous veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21439757" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Three-year European follow-up of endovenous radiofrequency-powered segmental thermal ablation of the great saphenous vein with or without treatment of calf varicosities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21172581" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Laser saphenous ablations in more than 1,000 limbs with long-term duplex examination follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31095724" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Randomized clinical trial of endovenous laser ablation versus direct and indirect radiofrequency ablation for the treatment of great saphenous varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27552990" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Endovenous laser ablation versus mechanochemical ablation with ClariVein(®) in the management of superficial venous insufficiency (LAMA trial): study protocol for a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23141679" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Postoperative pain and early quality of life after radiofrequency ablation and mechanochemical endovenous ablation of incompetent great saphenous veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24726004" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Mechanochemical endovenous Ablation versus RADiOfrequeNcy Ablation in the treatment of primary great saphenous vein incompetence (MARADONA): study protocol for a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25193822" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Intra-procedural pain score in a randomised controlled trial comparing mechanochemical ablation to radiofrequency ablation: The Multicentre Venefit™versus ClariVein®for varicose veins trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18431342" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Systematic review and meta-analysis of endovenous radiofrequency obliteration, endovenous laser therapy, and foam sclerotherapy for primary varicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18692348" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Endovenous therapies of lower extremity varicosities: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16052388" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Radiofrequency endovenous obliteration versus stripping of the long saphenous vein in the management of primary varicose veins: 3-year outcome of a randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17437986" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Radiofrequency ablation of incompetent perforator veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16376208" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A prospective study of the fate of venous leg perforators after varicose vein surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19299275" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Five-year results of incompetent perforator vein closure using TRans-Luminal Occlusion of Perforator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18295441" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : High ligation combined with stripping and endovenous laser ablation of the great saphenous vein: early results of a randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18278775" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Randomized clinical trial comparing endovenous laser ablation with surgery for the treatment of primary great saphenous varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20064730" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Randomised clinical trial comparing endovenous laser ablation with stripping of the great saphenous vein: clinical outcome and recurrence after 2 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16643080" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Endovenous ablation of incompetent saphenous veins: a large single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16763541" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The first 1000 cases of Italian Endovenous-laser Working Group (IEWG). Rationale, and long-term outcomes for the 1999-2003 period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18155001" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Endovenous 980-nm laser treatment of saphenous veins in a series of 500 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16990464" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Endovenous laser ablation of the great saphenous vein with a 980-nm diode laser in continuous mode: early treatment failures and successful repeat treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21724104" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Expanding the role of endovenous laser therapy: results in large diameter saphenous, small saphenous, and anterior accessory veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24845915" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Role of endovenous laser therapy in large and very large diameter great saphenous veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26065928" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Efficacy and Safety of Endovenous Laser Ablation in Very Large and Tortuous Great Saphenous Veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25305462" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Endovenous laser ablation in patients with wide diameter of the proximal segment of the great saphenous vein: Comparison of methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17349373" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Treatment of incompetent vein of Giacomini (thigh extension branch).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17331749" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Endovenous laser ablation (EVLA) of great saphenous vein to abolish "paradoxical reflux" in the Giacomini vein: a short report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19702351" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Endovenous thermal ablation of superficial venous insufficiency of the lower extremity: single-center experience with 3000 limbs treated in a 7-year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18619773" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Endovenous laser ablation for short saphenous vein incompetence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19580364" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Endovenous laser therapy of the small saphenous vein: patient satisfaction and short-term results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19201621" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Endovenous laser ablation (EVLA) of the anterior accessory great saphenous vein (AAGSV): abolition of sapheno-femoral reflux with preservation of the great saphenous vein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19341887" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Endovenous laser treatment of the small saphenous vein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22156157" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Results of radiofrequency ablation of the small saphenous vein in the supine position.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20115986" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Hearing evaluation of intratympanic methylprednisolone perfusion for refractory sudden sensorineural hearing loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20115986" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Hearing evaluation of intratympanic methylprednisolone perfusion for refractory sudden sensorineural hearing loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21658887" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Endovenous ablation of incompetent perforating veins is effective treatment for recalcitrant venous ulcers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24406088" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Factors that influence perforator thrombosis and predict healing with perforator sclerotherapy for venous ulceration without axial reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25920631" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Editor's Choice - Management of Chronic Venous Disease: Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18639418" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Endovenous laser and echo-guided foam ablation in great saphenous vein reflux: one-year follow-up results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16387263" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Endovenous ablation of truncal veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17134432" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Intravascular lasers in the treatment of varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24474721" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Predictors of recurrence of great saphenous vein reflux following treatment with ultrasound-guided foamsclerotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26163507" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A review of randomised controlled trials comparing ultrasound-guided foam sclerotherapy with endothermal ablation for the treatment of great saphenous varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8227108" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The functional long-term value of different types of treatment for saphenous vein incompetence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10917577" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Endovascular sclerotherapy, surgery, and surgery plus sclerotherapy in superficial venous incompetence: a randomized, 10-year follow-up trial--final results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12785023" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Foam-sclerotherapy, surgery, sclerotherapy, and combined treatment for varicose veins: a 10-year, prospective, randomized, controlled, trial (VEDICO trial).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15495134" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Surgery versus sclerotherapy for the treatment of varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22540961" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Ultrasound-guided foam sclerotherapy for treating incompetent great saphenous veins--results of 5 years of analysis and morphologic evolvement study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14692919" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Microfoam ultrasound-guided sclerotherapy of varicose veins in 100 legs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20729105" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Duplex ultrasound outcomes following ultrasound-guided foam sclerotherapy of symptomatic primary great saphenous varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19847863" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Medium-term results of ultrasound-guided foam sclerotherapy for small saphenous varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23312507" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Mechanochemical endovenous ablation of small saphenous vein insufficiency using the ClariVein(®) device: one-year results of a prospective series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16520171" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The effect of ultrasound-guided sclerotherapy of incompetent perforator veins on venous clinical severity and disability scores.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26946910" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Current state of the treatment of perforating veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23768792" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Randomized clinical trial comparing endovenous laser ablation and stripping of the great saphenous vein with clinical and duplex outcome after 5 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25342648" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Endovenous laser ablation with and without high ligation compared to high ligation and stripping for treatment of great saphenous varicose veins: Results of a multicentre randomised controlled trial with up to 6 years follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21638277" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Clinical and technical outcomes from a randomized clinical trial of endovenous laser ablation compared with conventional surgery for great saphenous varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26602795" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Five-year follow-up of a randomized, controlled trial comparing saphenofemoral ligation and stripping of the great saphenous vein with endovenous laser ablation (980 nm) using local tumescent anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21931012" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Comparable effectiveness of endovenous laser ablation and high ligation with stripping of the great saphenous vein: two-year results of a randomized clinical trial (RELACS study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17636511" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Systematic review of foam sclerotherapy for varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17054141" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Injection sclerotherapy for varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19620701" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Prospective five-year study of ultrasound-guided foam sclerotherapy in the treatment of great saphenous vein reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14725657" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21283981" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Randomized clinical trial of endovenous laser ablation compared with conventional surgery for great saphenous varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17600655" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Randomized trial comparing endovenous laser ablation of the great saphenous vein with high ligation and stripping in patients with varicose veins: short-term results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20473992" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Randomized clinical trial of VNUS ClosureFAST radiofrequency ablation versus laser for varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16336888" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Comparison of endovenous treatment with an 810 nm laser versus conventional stripping of the great saphenous vein in patients with primary varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25274220" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Cost-effectiveness of ultrasound-guided foam sclerotherapy, endovenous laser ablation or surgery as treatment for primary varicose veins from the randomized CLASS trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25251616" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : A randomized trial comparing treatments for varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31483962" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Five-Year Outcomes of a Randomized Trial of Treatments for Varicose Veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12839217" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Long term results of compression sclerotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2324369" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Resolution of pain associated with varicose and telangiectatic leg veins after compression sclerotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16171596" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Long-term outcomes of endovenous radiofrequency obliteration of saphenous reflux as a treatment for superficial venous insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12042730" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Endovascular obliteration of saphenous reflux: a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18992425" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The present status of surgery of the superficial venous system in the management of venous ulcer and the evidence for the role of perforator interruption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9808850" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Saphenous surgery does not correct perforator incompetence in the presence of deep venous reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17701962" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Randomized clinical trial of the effect of adding subfascial endoscopic perforator surgery to standard great saphenous vein stripping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29688123" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : A Randomized Trial of Early Endovenous Ablation in Venous Ulceration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14981453" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Systematic review of outcomes after surgical management of venous disease incorporating subfascial endoscopic perforator surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22133452" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : The impact of ablation of incompetent superficial and perforator veins on ulcer healing rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19767487" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Treatment of incompetent perforating veins using the radiofrequency ablation stylet: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20523994" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Endovenous ablation for the treatment of chronic venous insufficiency and venous ulcerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20875753" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Healing and recurrence rates following ultrasound-guided foam sclerotherapy of superficial venous reflux in patients with chronic venous ulceration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19797263" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Effectiveness of foam sclerotherapy for the treatment of varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20006528" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Randomised clinical trial of foam sclerotherapy for patients with a venous leg ulcer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20537570" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Laser and radiofrequency ablation study (LARA study): a randomised study comparing radiofrequency ablation and endovenous laser ablation (810 nm).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20638231" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : A randomized, controlled trial of endovenous thermal ablation using the 810-nm wavelength laser and the ClosurePLUS radiofrequency ablation methods for superficial venous insufficiency of the great saphenous vein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21934487" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : A prospective double-blind randomized controlled trial of radiofrequency versus laser treatment of the great saphenous vein in patients with varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19628516" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Saphenous laser ablation at 1470 nm targets the vein wall, not blood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20801608" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Prospective randomized trial comparing endovenous laser ablation and surgery for treatment of primary great saphenous varicose veins with a 2-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29786478" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23160149" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Randomized clinical trial of endovenous laser ablation versus conventional surgery for small saphenous varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12021712" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Endovenous obliteration versus conventional stripping operation in the treatment of primary varicose veins: a randomized controlled trial with comparison of the costs.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
